FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include Patients with PSMA Positive mCRPC By Ogkologos - April 25, 2025 525 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PSMAfore study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Neoadjuvant Treatment with Dual Immune Checkpoint Inhibitors Plus Chemotherapy Produces Numerically... March 23, 2023 Immunoscore Classification Significantly Associates with Time to Recurrance In Asian Patients... November 21, 2020 Expression of AR-regulated Genes in CTCs Is Prognostic for Survival and... July 7, 2021 Grandparents of children with cancer: “I would never want to go... September 1, 2020 Load more HOT NEWS Survival Benefit of Enfortumab Vedotin and Pembrolizumab Compared with Chemotherapy in... Surgical Technique Helps Keep Breast Cancer Patients from Going Under the... What to Do When You Are Diagnosed With Cancer During Pregnancy Looking to Help Rebuild Strength After Breast Cancer Treatment? Soccer May...
